SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Iovance Biotherapeutics filed an 8-K with an updated corporate…

IOVANCE BIOTHERAPEUTICS, INC. · 8-K filed Aug 6, 2026 at 17:30 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Aug 6, 2026 at 17:30 ET

Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presentation highlights ~66% YoY revenue growth in Q2 2026, a ~$99M quarterly revenue >10% above guidance, ~56% gross margin from cost of sales, and ~$304M cash runway into 2H 2028. The filing is a routine business update with no material new events beyond the existing pipeline and commercial progress.

  • 2Q26 revenue ~$99M, >10% above guidance, ~66% YoY growth
  • Cash position ~$304M as of June 30, 2026, runway into 2H 2028
  • ~56% gross margin from cost of sales in 2Q26, 50% YTD
  • >95 authorized treatment centers in North America

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access